logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Bioverativ Therapeutics Inc.

Calculating rank
USPTO Granted Patents = 76

% Expired Patents = 9.2



Trademarks = 6

Forward Citations = 270

Loading Chart...
Loading Chart...

91 inventors (with patents filed for the assignee):

goldMedal Robert T Peters (40 out of 63 patents)

silverMedal Haiyan Jiang (25 out of 30 patents)

bronzeMedal Glenn Pierce (19 out of 25 patents)

4.  Tongyao Liu (16 out of 16 patents)

5.  Susan C Low (10 out of 21 patents)

6.  Samantha Truex (10 out of 11 patents)

7.  John D Kulman (10 out of 21 patents)

8.  Alan J Bitonti (8 out of 43 patents)

9.  Ekta Seth Chhabra (8 out of 8 patents)

10.  Jurg Sommer (8 out of 10 patents)

11.  Jennifer A Dumont (7 out of 18 patents)

12.  Joe Salas (7 out of 9 patents)

13.  Adam Robert Mezo (7 out of 24 patents)

14.  Siyuan Tan (5 out of 18 patents)

15.  Daniel S Rivera (4 out of 11 patents)


Core Competencies:
Factor VIII
Chimeric Proteins
Gene Therapy
Immunogenicity
Hemophilia
Polypeptide Formulations
Viral Vectors
Procoagulant Compounds
Blood Factor Monitoring
Purification Methods
Optimized Genes
Clotting Factors

76 patents:

1. 12653871 - FACTOR IX POLYPEPTIDE FORMULATIONS (2026-06-16),
2. 12617839 - Factor VIII chimeric proteins and uses thereof (2026-05-05),
3. 12551404 - Device container (2026-02-17),
4. 12403183 - Factor VIII polypeptide formulations (2025-09-02),
5. 12403164 - Lentiviral vector formulations (2025-09-02),
6. 12371747 - Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy (2025-07-29),
7. 12364774 - Nucleic acid molecules and uses thereof for non-viral gene therapy (2025-07-22),
8. 12275970 - Optimized factor IX gene (2025-04-14),
9. 12257288 - Methods of inducing immune tolerance to clotting factors (2025-03-25),
10. 12186375 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof (2025-01-07),
11. 12173307 - Methods for the purification of viral vectors (2024-12-24),
12. 12168776 - Nucleic acid molecules and uses thereof (2024-12-17),
13. 12161696 - Methods of treating hemophilic arthropathy using chimeric clotting factors (2024-12-10),
14. 12134632 - On-column viral inactivation methods (2024-11-05),
15. 12128092 - Lyophilized factor IX formulations (2024-10-29),
Company Overview
Bioverativ Therapeutics Inc., based in Waltham, MA, specializes in the development of innovative therapies for hemophilia and other rare blood disorders. The company focuses on chimeric proteins and gene therapy, leveraging advanced technologies such as viral vectors and polypeptide formulations to create effective treatments. With a commitment to addressing immunogenicity and enhancing procoagulant compounds, Bioverativ aims to improve patient outcomes and quality of life in the field of hematology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

76 Patents

#22 in Waltham, MA

#268 in Massachusetts

#4,846 in US

#9,898 in the World

Waltham, MA (US)
Waltham, MA, United States of America

Bioverativ Therapeutics Inc.

Forward Citations = 270

91 inventors:

goldMedal Robert T Peters (40 out of 63 patents)

silverMedal Haiyan Jiang (25 out of 30 patents)

bronzeMedal Glenn Pierce (19 out of 25 patents)

4.  Tongyao Liu (16 out of 16 patents)

5.  Susan C Low (10 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bioverativ Therapeutics Inc.. Retrieved from https://idiyas.com/company/bioverativ-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…